JP Morgan analyst Priyanka Grover maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight an

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology (NASDAQ:BBOT) reported quarterly losses of $(705.20) per share which missed the a

Continued to advance monotherapy and combination cohorts for all clinical programs Initiated dosing

Shares of BridgeBio Oncology Therapeutics, Inc (NASDAQ: BBOT - Get Free Report) have earned an avera

BridgeBio Oncology Therapeutics remains a Buy, despite a >30% decline since prior coverage, supporte

U.S. stocks fell, Nasdaq down 100 points. Penguin Solutions Inc (PENG) rose 18.8% after better-than-

JP Morgan analyst Priyanka Grover initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a O

Oppenheimer analyst Mazahir Alimohamed assumes BridgeBio Oncology (NASDAQ:BBOT) with a Outperform

BridgeBio Oncology (NASDAQ:BBOT) reported quarterly losses of $(526.11).This is a 870.15 percent dec

SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc.

SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc.,

Top Wall Street analysts changed outlook on top names. For full rating changes, check analyst rating

Pre-Market Stock Futures: Futures are trading mixed as we get set to start the new trading week, as

Canaccord Genuity analyst John Newman initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with

BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceut

BBO-11818 targets KRAS in both its ON (active GTP-bound) and OFF (inactive GDP-bound) states, potent

BridgeBio Oncology Therapeutics, Inc. ("BBOT") (Nasdaq: BBOT), a clinical-stage biopharmaceu

Pedro J. Beltran, PhD, a seasoned executive who previously served as Chief Scientific Officer of BBO

BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceut

BBO-10203 physically and allosterically disrupts the interaction between RAS and PI3Kα, leading to s

BridgeBio Oncology Therapeutics is advancing differentiated KRAS inhibitors, targeting both active a

BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally adv

BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally adv

SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc

BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the O

BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the O

HC Wainwright & Co. analyst Robert Burns maintains BridgeBio Oncology (NASDAQ:BBOT) with a Bu

BridgeBio Oncology (NASDAQ:BBOT) reported quarterly losses of $(0.49) per share which beat the analy

BBOT debuted as a publicly traded oncology company developing a differentiated portfolio of three cl

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc.

SOUTH SAN FRANCISCO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc.

Stifel analyst Laura Prendergast initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Bu

Pre-Market Stock Futures: Futures are trading higher after a stellar and surprising January jobs rep

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc. (BBOT) Discusses Clinical Data Updates for BBO-8520, BBO-11818

Raymond James analyst Sean McCutcheon initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with

Wedbush analyst David Nierengarten reiterates BridgeBio Oncology (NASDAQ:BBOT) with a Outperform

Morgan Stanley analyst Sean Laaman initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a

Wedbush analyst David Nierengarten reiterates BridgeBio Oncology (NASDAQ:BBOT) with a Outperform

Oppenheimer analyst Matthew Biegler maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform

Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT signal

Data demonstrate potent suppression of MAPK signaling and viability in KRAS mutant cell lines, as we

BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceut

Leerink Partners analyst Andrew Berens initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) wit

HC Wainwright & Co. analyst Robert Burns initiates coverage on BridgeBio Oncology (NASDAQ:BBO